Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
-
* Corresponding author: George W Sledge gsledge@iupui.edu
Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA
Breast Cancer Research 2009, 11:303 doi:10.1186/bcr2250
Published: 18 May 2009Abstract
Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?